Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Anthropometric Measures and Prediction of Maternal Sleep-Disordered Breathing.

Bourjeily G, Chambers A, Salameh M, Bublitz MH, Kaur A, Coppa A, Risica P, Lambert-Messerlian G.

J Clin Sleep Med. 2019 Jun 15;15(6):849-856. doi: 10.5664/jcsm.7834.

PMID:
31138388
2.

Maternal BMI, Peripheral Deiodinase Activity, and Plasma Glucose: Relationships Between White Women in the HAPO Study.

Haddow JE, Metzger BE, Lambert-Messerlian G, Eklund E, Coustan D, Catalano P, Palomaki GE.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2593-2600. doi: 10.1210/jc.2018-02328.

PMID:
30753726
3.

Fewer women aged 35 and older choose serum screening for Down's syndrome: Impact and implications.

Lambert-Messerlian G, Palomaki GE.

J Med Screen. 2019 Jun;26(2):59-66. doi: 10.1177/0969141318797961. Epub 2018 Sep 25.

PMID:
30253677
4.

Peripheral deiodinase activity: A potential explanation for the association between maternal weight and gestational hyperglycemia.

Haddow JE, Lambert-Messerlian G, Eklund E, Neveux LM, Palomaki GE.

Obstet Med. 2018 Jun;11(2):73-78. doi: 10.1177/1753495X17733223. Epub 2017 Oct 12.

5.

Snoring and markers of fetal and placental wellbeing.

Salameh M, Lee J, Palomaki G, Eklund E, Curran P, Suarez JAR, Lambert-Messerlian G, Bourjeily G.

Clin Chim Acta. 2018 Oct;485:139-143. doi: 10.1016/j.cca.2018.06.039. Epub 2018 Jun 26.

6.

Reproductive health, obesity, and cardiometabolic risk factors among Samoan women.

Maredia H, Hawley NL, Lambert-Messerlian G, Fidow U, Reupena MS, Naseri T, McGarvey ST.

Am J Hum Biol. 2018 May;30(3):e23106. doi: 10.1002/ajhb.23106. Epub 2018 Apr 16.

7.

Current and Emerging Multianalyte Assays with Algorithmic Analyses-Are Laboratories Ready for Clinical Adoption?

Colón-Franco JM, Bossuyt PMM, Algeciras-Schimnich A, Bird C, Engstrom-Melnyk J, Fleisher M, Kattan M, Lambert-Messerlian G.

Clin Chem. 2018 Jun;64(6):885-891. doi: 10.1373/clinchem.2017.275677. Epub 2018 Jan 17. No abstract available.

8.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A; University of California, San Francisco MS-EPIC Team,, Bacchetti P, Hauser SL, Oksenberg JR.

Neurology. 2018 Jan 16;90(3):e254-e260. doi: 10.1212/WNL.0000000000004843. Epub 2017 Dec 22.

9.

Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia.

Rehfeldt M, Eklund E, Struck J, Sparwasser A, O'Brien B, Palomaki GE, Köhrle J, Bergmann A, Lambert-Messerlian G.

Pregnancy Hypertens. 2018 Jan;11:124-128. doi: 10.1016/j.preghy.2017.11.001. Epub 2017 Nov 7.

PMID:
29133069
10.

Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS.

Garg D, Grazi R, Lambert-Messerlian GM, Merhi Z.

J Assist Reprod Genet. 2017 Nov;34(11):1507-1513. doi: 10.1007/s10815-017-1011-6. Epub 2017 Aug 19.

11.

Measuring maternal serum screening markers for Down's syndrome in plasma collected for cell-free DNA testing.

Lambert-Messerlian GM, Eklund EE, Neveux LM, Palomaki GE.

J Med Screen. 2017 Sep;24(3):113-119. doi: 10.1177/0969141316670193. Epub 2016 Oct 21.

PMID:
28756761
12.

Assessment of serum HE4 levels throughout the normal menstrual cycle.

Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, Eklund E, Lambert-Messerlian G.

Am J Obstet Gynecol. 2017 Jul;217(1):53.e1-53.e9. doi: 10.1016/j.ajog.2017.02.029. Epub 2017 Feb 22.

PMID:
28237871
13.

Oxidative and carbonyl stress in pregnant women with obstructive sleep apnea.

Khan N, Lambert-Messerlian G, Monteiro JF, Hodosy J, Tóthová Ľ, Celec P, Eklund E, Curran P, Bourjeily G.

Sleep Breath. 2018 Mar;22(1):233-240. doi: 10.1007/s11325-017-1475-8. Epub 2017 Feb 24.

14.

Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA.

O'Brien BM, Halliday J, Lambert-Messerlian G, Eklund EE, Kloza E, Palomaki GE.

Prenat Diagn. 2017 Mar;37(3):303-305. doi: 10.1002/pd.5010. Epub 2017 Feb 17. No abstract available.

PMID:
28124379
15.

Serum Progesterone Levels in Pregnant Women with Obstructive Sleep Apnea: A Case Control Study.

Lee J, Eklund EE, Lambert-Messerlian G, Palomaki GE, Butterfield K, Curran P, Bourjeily G.

J Womens Health (Larchmt). 2017 Mar;26(3):259-265. doi: 10.1089/jwh.2016.5917. Epub 2017 Jan 19.

16.

The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population.

Palomaki GE, Kloza EM, O'Brien BM, Eklund EE, Lambert-Messerlian GM.

Genet Med. 2017 Jul;19(7):778-786. doi: 10.1038/gim.2016.194. Epub 2017 Jan 12.

17.

A First-Trimester Biomarker Panel for Predicting the Development of Gestational Diabetes.

Farina A, Eklund E, Bernabini D, Paladino M, Righetti F, Monti G, Lambert-Messerlian G.

Reprod Sci. 2017 Jun;24(6):954-959. doi: 10.1177/1933719116675057. Epub 2016 Nov 12.

PMID:
27837083
18.

Where have all the trisomies gone?

Palomaki GE, Lambert-Messerlian GM, Haddow JE.

Am J Obstet Gynecol. 2016 Nov;215(5):583-587.e1. doi: 10.1016/j.ajog.2016.06.046.

PMID:
27793310
19.

Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women.

Scherzer R, Greenblatt RM, Merhi ZO, Kassaye S, Lambert-Messerlian G, Maki PM, Murphy K, Karim R, Bacchetti P.

Am J Obstet Gynecol. 2017 Jan;216(1):46.e1-46.e11. doi: 10.1016/j.ajog.2016.07.048. Epub 2016 Jul 26.

20.

Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes.

Haddow JE, Craig WY, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

PLoS One. 2016 Feb 24;11(2):e0149065. doi: 10.1371/journal.pone.0149065. eCollection 2016.

21.

Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population.

Maredia H, Lambert-Messerlian GM, Palomaki GE, Viali S, Hawley NL, McGarvey ST.

Clin Biochem. 2016 Jul;49(10-11):782-6. doi: 10.1016/j.clinbiochem.2016.02.006. Epub 2016 Feb 18.

22.

Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.

Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R.

J Clin Endocrinol Metab. 2015 Nov;100(11):4307-14. doi: 10.1210/jc.2015-2580. Epub 2015 Oct 20.

PMID:
26485217
23.

Levels of antimüllerian hormone in serum during the normal menstrual cycle.

Lambert-Messerlian G, Plante B, Eklund EE, Raker C, Moore RG.

Fertil Steril. 2016 Jan;105(1):208-13.e1. doi: 10.1016/j.fertnstert.2015.09.033. Epub 2015 Oct 23.

PMID:
26477497
24.

Comparison of Inhibin Alpha Subunit and Antimüllerian Hormone Immunoreactivity in Granulosa Cell and Mucinous Ovarian Tumors.

Lambert-Messerlian G, Steinhoff M, Kumar A, Eklund EE, Moore R.

Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):71-77.

PMID:
26469329
25.

Prenatal serum screening markers may not require adjustment in former smokers.

Lambert-Messerlian G, Palomaki GE.

Prenat Diagn. 2015 Dec;35(13):1371-3. doi: 10.1002/pd.4695. Epub 2015 Nov 5. No abstract available.

PMID:
26413989
26.

Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.

Lokich E, Palisoul M, Romano N, Craig Miller M, Robison K, Stuckey A, DiSilvestro P, Mathews C, Granai CO, Lambert-Messerlian G, Moore RG.

Gynecol Oncol. 2015 Nov;139(2):248-52. doi: 10.1016/j.ygyno.2015.09.010. Epub 2015 Sep 11.

27.

Evidence of Placental Hypoxia in Maternal Sleep Disordered Breathing.

Ravishankar S, Bourjeily G, Lambert-Messerlian G, He M, De Paepe ME, Gündoğan F.

Pediatr Dev Pathol. 2015 Sep-Oct;18(5):380-6. doi: 10.2350/15-06-1647-OA.1. Epub 2015 Jul 17.

PMID:
26186234
28.

Use of first or second trimester serum markers, or both, to predict preeclampsia.

Lambert-Messerlian G, Eklund EE, Chien EK, Rosene-Montella K, Neveux LM, Haddow HR, Palomaki GE.

Pregnancy Hypertens. 2014 Oct;4(4):271-8. doi: 10.1016/j.preghy.2014.07.001. Epub 2014 Jul 29.

PMID:
26104816
29.

An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism.

Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME.

Thyroid. 2015 Aug;25(8):949-53. doi: 10.1089/thy.2015.0085. Epub 2015 Jun 23.

30.
31.

Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?

Palomaki GE, Ashwood ER, Best RG, Lambert-Messerlian G, Knight GJ.

Genet Med. 2015 Nov;17(11):897-900. doi: 10.1038/gim.2015.39. Epub 2015 Apr 2.

PMID:
25834952
32.

Circulating cell free DNA testing: are some test failures informative?

Palomaki GE, Kloza EM, Lambert-Messerlian GM, van den Boom D, Ehrich M, Deciu C, Bombard AT, Haddow JE.

Prenat Diagn. 2015 Mar;35(3):289-93. doi: 10.1002/pd.4541. Epub 2015 Jan 8.

PMID:
25449554
33.

Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy.

Kloza EM, Haddow PK, Halliday JV, O'Brien BM, Lambert-Messerlian GM, Palomaki GE.

J Genet Couns. 2015 Apr;24(2):259-66. doi: 10.1007/s10897-014-9758-8. Epub 2014 Sep 10.

PMID:
25204423
34.

Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center.

O'Brien BM, Kloza EM, Halliday JV, Lambert-Messerlian GM, Palomaki GE.

Genet Test Mol Biomarkers. 2014 Oct;18(10):665-9. doi: 10.1089/gtmb.2014.0125. Epub 2014 Aug 19.

PMID:
25137409
35.

Lethal hypoplasia and developmental anomalies of the lungs in a newborn with intrauterine adrenal hemorrhage and cerebral infarcts: a proposed pulmonary disruption sequence.

Lertsburapa T, Vargas D, Lambert-Messerlian G, Tantravahi U, Gündoğan F, DeLaMonte S, Coyle MG, De Paepe ME.

Pediatr Dev Pathol. 2014 Sep-Oct;17(5):374-81. doi: 10.2350/14-05-1485-CR.1. Epub 2014 Jun 27.

PMID:
24971487
36.

Placenta-secreted circulating markers in pregnant women with obstructive sleep apnea.

Bourjeily G, Curran P, Butterfield K, Maredia H, Carpenter M, Lambert-Messerlian G.

J Perinat Med. 2015 Jan;43(1):81-7. doi: 10.1515/jpm-2014-0052.

PMID:
24846956
37.

Obstructive sleep apnea is associated with alterations in markers of fetoplacental wellbeing.

Bourjeily G, Butterfield K, Curran P, Lambert-Messerlian G.

J Matern Fetal Neonatal Med. 2015 Feb;28(3):262-6. doi: 10.3109/14767058.2014.913131. Epub 2014 May 14.

PMID:
24712853
38.

Implications of High Free Thyroxine (FT4) concentrations in euthyroid pregnancies: the FaSTER trial.

Haddow JE, Craig WY, Neveux LM, Haddow HR, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

J Clin Endocrinol Metab. 2014 Jun;99(6):2038-44. doi: 10.1210/jc.2014-1053. Epub 2014 Feb 28.

39.

Down syndrome screening: suitability of a WHO 5 standardized total hCG assay.

Palomaki GE, Lambert-Messerlian G.

Clin Biochem. 2014 May;47(7-8):629-31. doi: 10.1016/j.clinbiochem.2014.01.013. Epub 2014 Jan 23.

PMID:
24462966
40.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK.

Sci Rep. 2014 Jan 6;4:3574. doi: 10.1038/srep03574.

41.

Multisite evaluation of a monoclonal IMMULITE erythropoietin immunoassay.

Owen WE, Lambert-Messerlian G, Delaney C, Christenson R, Plouffe B, Ludewig R, Woods A, Lei JD, Thompson S, Roberts WL, Straseski JA.

Clin Biochem. 2014 Feb;47(3):216-9. doi: 10.1016/j.clinbiochem.2013.11.012. Epub 2013 Nov 26.

PMID:
24291051
42.

Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies.

Lambert-Messerlian G, Kloza EM, Williams J 3rd, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, De Biasio P, Borrell A, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE.

Genet Med. 2014 May;16(5):419-22. doi: 10.1038/gim.2013.149. Epub 2013 Oct 3.

PMID:
24091801
43.

The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies.

Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE.

Prenat Diagn. 2013 Jul;33(7):667-74. doi: 10.1002/pd.4126. Epub 2013 May 31.

PMID:
23592541
44.

Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening.

Lambert-Messerlian GM, Palomaki GE, Eklund EE, Kloza EM, Neveux LM, Phipps MG, Canick JA.

J Med Screen. 2012 Dec;19(4):164-70. doi: 10.1258/jms.2012.012086. Epub 2012 Dec 31.

PMID:
23277614
45.

Impact of adjusting for the reciprocal relationship between maternal weight and free thyroxine during early pregnancy.

Haddow JE, Craig WY, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, D'Alton ME; First And Second Trimester Risk Of Aneuploidy Faster Research Consortium.

Thyroid. 2013 Feb;23(2):225-30. doi: 10.1089/thy.2012.0440.

46.

DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations.

Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE.

Prenat Diagn. 2012 Aug;32(8):730-4. doi: 10.1002/pd.3892. Epub 2012 May 14.

PMID:
22585317
47.

Expression of transcription factors controlling alpha inhibin gene expression in placental tissues from pregnancies affected by fetal Down syndrome.

Kipp JL, Lambert-Messerlian G, Eklund E, Rodriguez G, Demczuk M, Gundogan F.

Prenat Diagn. 2012 Mar;32(3):302-5. doi: 10.1002/pd.3826. No abstract available.

PMID:
22430733
48.

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G.

Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7. doi: 10.1016/j.ajog.2011.12.028. Epub 2011 Dec 30.

49.

Expression of inhibin/activin proteins and receptors in the human hypothalamus and basal forebrain.

Miller MC, Lambert-Messerlian GM, Eklund EE, Heath NL, Donahue JE, Stopa EG.

J Neuroendocrinol. 2012 Jun;24(6):962-72. doi: 10.1111/j.1365-2826.2012.02289.x.

PMID:
22296042
50.

Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC Jr.

Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029. Epub 2011 Dec 30.

Supplemental Content

Loading ...
Support Center